Skip to content
lifestyle.wordsjournal.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Teva Pharmaceutical Industries Ltd
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
August 19, 2026
Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy
August 11, 2026
Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy
July 29, 2026
Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact
May 22, 2026
Teva to Present at the BofA Securities Health Care Conference
May 4, 2026
Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets
April 30, 2026
Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
April 29, 2026
Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
April 29, 2026
Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners
April 15, 2026
Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics
April 14, 2026
1
2
Next Page
→